VLDL lipidomics reveals hepatocellular lipidome changes in metabolic dysfunction–associated steatotic liver disease
Authors:
- David Guardamino OjedaDODavid Guardamino Ojeda
- Yusuf YalcinYYYusuf Yalcin
- Yered Pita-JuarezYPYered Pita-Juarez
- Aaron HakimAHAaron Hakim
- Susmita BhattaraiSBSusmita Bhattarai
- Zsu-Zsu ChenZCZsu-Zsu Chen
- John M. AsaraJohn M. Asara
- Margery A. ConnellyMargery A. Connelly
- Melissa R. MillerMMMelissa R. Miller
- Michelle LaiMLMichelle Lai
- Z. Gordon JiangZJZ. Gordon Jiang
Open Access
- 23 May 2025
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 9 (6)
Abstract
Background: The production of VLDL is one of the primary mechanisms through which liver cells regulate intracellular lipid homeostasis. We hypothesize that the disease characteristics of metabolic dysfunction–associated steatotic liver disease (MASLD) differentially impact VLDL lipid composition. This study comprehensively examines the relationship between VLDL-lipidome and MASLD histology and disease-associated genetics, aiming to define MASLD-related VLDL changes. Methods: We performed untargeted lipidomics on serum VLDL particles in a cohort of biopsy-proven MASLD patients to examine the relationship between VLDL-lipidome and MASLD disease features as well as MASLD-related genetic variants. Results: Among 1514 detected lipid species in VLDL, triglyceride (TG), phosphatidylcholine (PC), and ceramide (Cer) were the top classes. Moderate to severe hepatic steatosis was associated an increase in VLDL-TG, especially those with palmitic acid (C16:0). A unified acyl chain distribution analysis revealed that steatosis was associated with increases in TGs with saturated and monounsaturated fatty acyl chains, but decreases in polyunsaturated fatty acyl chains, a pattern that was not mirrored in acyl chains from VLDL-PC or VLDL-Cer. Lobular inflammation was associated with reductions in lipids with polyunsaturated acyl chains, particularly docosahexaenoic acid (C22:6). Meanwhile, patients with advanced liver fibrosis (stages 3–4) had reductions in VLDL-TGs with both saturated and polyunsaturated acyl chains and overall enrichment in Cer species. Furthermore, MASLD-associated genetic variants in PNPLA3, TM6SF2, GPAM, HSD17B13, and MTARC1 demonstrated distinct VLDL-lipidomic signatures in keeping with their biology in lipoprotein metabolism. Conclusions: Hepatic steatosis and liver fibrosis in MASLD are associated with distinct VLDL-lipidomic signatures, respectively. This relationship is further modified by MASLD-genetics, suggesting a differential impact of pathogenic features on hepatocellular lipid homeostasis.Keywords
This publication has 50 references indexed in Scilit:
- The plasma lipidomic signature of nonalcoholic steatohepatitis†‡Hepatology, 2009
- Dysfunctional very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis # †Hepatology, 2009
- Serum saturated fatty acids containing triacylglycerols are better markers of insulin resistance than total serum triacylglycerol concentrationsDiabetologia, 2009
- Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver diseaseNature Genetics, 2008
- PLINK: A Tool Set for Whole-Genome Association and Population-Based Linkage AnalysesThe American Journal of Human Genetics, 2007
- A lipidomic analysis of nonalcoholic fatty liver diseaseHepatology, 2007
- Probabilistic Quotient Normalization as Robust Method to Account for Dilution of Complex Biological Mixtures. Application in 1H NMR MetabonomicsAnalytical Chemistry, 2006
- Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver diseaseJournal of Clinical Investigation, 2005
- Nonalcoholic Fatty Liver DiseaseNew England Journal of Medicine, 2002
- Lipoprotein Isolation and Analysis from Serum by Preparative Ultracentrifugation2000